Stock IONS IONIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Real-time Estimate Cboe BZX
Other stock markets
 01:08:42 2024-04-23 pm EDT 		5-day change 1st Jan Change
42.11 USD +2.53% Intraday chart for Ionis Pharmaceuticals, Inc. +1.64% -16.54%
Apr. 11 North American Morning Briefing : Stock Futures -2- DJ
Apr. 10 Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ionis to hold first quarter 2024 financial results webcast
PR
North American Morning Briefing : Stock Futures -2-
DJ
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform
MT
North American Morning Briefing : Traders Await -2-
DJ
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating
MT
Ionis Pharmaceuticals : Listen to webcast
PU
Transcript : Ionis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 03:00 PM
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
AQ
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome
CI
Ionis to present at upcoming investor conferences
PR
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting
AQ
Transcript : Ionis Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:30 AM
Sector Update: Health Care Stocks Gain Premarket Wednesday
MT
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up
MT
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
RE
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
PR
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224
CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating
MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IONS Stock
  4. News Ionis Pharmaceuticals, Inc.